The rise of AI in the stock market has brought about new possibilities for traders and investors to make informed decisions. For EXAS, Tickeron's Earnings Trader (TA) bot has been one of the best performers in their robot factory. This particular bot is accessible through their website, and traders can use it to gain insights into potential trading opportunities. The bot leverages AI and technical analysis to provide recommendations for buying and selling EXAS stock.
As a technical analyst, it is important to stay up to date with the latest trends and signals in the stock market. In this article, we will take a closer look at Exact Sciences Corp (EXAS, $67.02) and its recent performance.
According to A.I.dvisor, EXAS is expected to experience a growth of 2% to reach $68.36 or more in the coming week. The stock has been on a winning streak for a consecutive week, and the odds of an Uptrend continuation are currently at 77%.
However, investors should be cautious as EXAS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on April 05, 2023. This indicates a bearish signal and suggests that the stock may decline going forward. Tickeron's A.I.dvisor has analyzed 47 instances where the MACD turned negative, and in 42 of those cases, the stock moved lower in the days that followed. This puts the odds of a downward move for EXAS at 89%.
While it is always important to be mindful of potential risks, it is worth noting that past performance does not guarantee future results. As such, investors should continue to monitor the market closely and make informed decisions based on current trends and signals.
If you're interested in stocks and want to stay ahead of the game, consider registering with us, click here. Our platform utilizes the power of AI to provide you with valuable insights and analysis, helping you make informed decisions when it comes to trading and investing. Don't miss out on this opportunity to take your stock market game to the next level. Register with us now and start making money!
The 10-day moving average for EXAS crossed bearishly below the 50-day moving average on July 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EXAS broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EXAS entered a downward trend on July 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where EXAS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 08, 2025. You may want to consider a long position or call options on EXAS as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for EXAS just turned positive on July 14, 2025. Looking at past instances where EXAS's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
EXAS moved above its 50-day moving average on July 14, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXAS advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.065) is normal, around the industry mean (24.413). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.074) is also within normal values, averaging (42.770).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of proprietary technologies for the detection of cancer
Industry MedicalSpecialties